Urteste made its debut on the NewConnect market
16:04
Biotechnology company specializing in creating an innovative technology that enables the detection of neoplastic diseases from urine samples, Urteste, made its debut on the NewConnect market on October 27.
475,412 series A shares, 24,588 series B shares, and 95,200 series C shares were introduced to trading on the NewConnect market. The funds will be used for research and development in the Panuri (pancreatic cancer) and Easy-Test (prostate cancer) projects and the development of another 13 diagnostic targets.
"The technology we are developing consists in detecting tumors by measuring the activity of enzymes present in the urine. The technology is based on a process in which, as a result of enzymatic hydrolysis (decomposition) of the compound, a chromophore molecule is released and the color changes over time. urine samples of cancer patients. Urteste technology is based on our own know-how, which is unique on a global scale," prof. Adam Lesner, co-founder, project initiator, and chairman of the Urteste Scientific Council, said.
